Tag Archives: Clostridioides difficile infection

Live-Online C. diff. Symposium developed to support and guide patients, families, and caregivers through a C. difficile illness

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021, from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or who have experienced CDI recurrences. The patients, family members, and caregivers will all benefit from the information and up-to-date data presented.

Presenters are among some of the top C diff. thought leaders and include healthcare professionals, practitioners, and educators who are helping to change the way individuals maneuver through a C. difficile infection, worldwide.

Unlike other presentations on this topic, C. diff. Survivors will share their C. diff. infection journeys to provide a real-world perspective on the patient experience. Other topics addressed will include creating a culture for patient-centered care, C. diff. innovations, diagnostics, research, environmental safety, clinical trials, and studies, C diff. in pediatric patients and more.

To register for this global live-online event, visit: https://cdifffoundation.org/patient-family-caregiver-symposium-july-16-2021/

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20 percent, the C Diff Foundation believes that the annual incidence in the U.S. approaches 600,000.

About Seres Therapeutics

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

It reported positive, topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI).

For more information: https://www.serestherapeutics.com/

About the C Diff Foundation

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation #cdiffpatientfamilycaregiver #cdiff2021 #cdiffwalks2021

C Diff Foundation(TM) is a trademark of the C Diff Foundation, established 2012 in the U.S.

The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021, from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or who have experienced CDI recurrences.

Related link: https://cdifffoundation.org/

C Diff Foundation Releases ‘C diff and You’ App for Patients, Families, and Caregivers

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation, the leading Global Patient and Healthcare Organization Educating and Advocating for C. difficile (Clostridioides difficile, C. diff., CDAD, CDI) today announced that the organization has developed a free mobile application designed specifically for patients and families who have been impacted by a Clostridioides difficile infection.

The free app, "C diff and You," is available on the Apple Store and Google Play, and was designed by the C Diff Foundation as an interactive educational tool allowing users to access easy-to-understand information about C. diff. infection prevention, treatments, clinical trials, support, nutrition, diagnostics, and environmental safety.

Clostridioides difficile infection, also called C. diff., CDI, C. difficile, or CDAD, is a life-threatening infection.

"I am really pleased to see this further addition to the C Diff Foundation's catalogue of achievements. This is an ideal way to communicate information far and wide," stated Professor Mark Wilcox, MD, FRCPath.

"There are patients, families, and caregivers isolated, and experiencing social-economic changes resulting from the COVID-19 pandemic. In the Global efforts to slow the spread of the COVID-19 virus the ramifications being witnessed range from loss of wages to difficulties meeting housing, utilities, nutrition, and healthcare expenses down to basic cable and internet connections. The one common denominator remaining accessible is the Mobile (also called Cell) phone. Developing the mobile application, 'C diff and You,' places the C. diff. community in the palm of their hands continuing to support the patients, families, and caregivers who desperately need to know that they are not alone no matter where they are," says Nancy C. Caralla, Founding President, and Executive Director of the C Diff Foundation.

Through the deployment of this app, the C Diff Foundation continues with its commitment to evolve resources to unite patients, families, and healthcare providers in the fight against C. diff. infections. The app focuses on quality resources directly relevant to patients and their care providers, aiming to lower the anxiety and fear associated with a CDI and provide easy access to reliable information to all users. "C diff and You" will also provide users with direct access to patient-centered care information, educational episodes of the "C. diff. Spores and More" archived radio episodes, and the C. diff. Global Tele-Support Network with a one tap key to "Sign Up Today" for Caregiver, Nutrition, and Physician support sessions. The telephone access key connects the app user directly to the C Diff Foundation office and the Foundation's Triage Nurses.

"Patients with a C. difficile infection are in desperate need for education on the risk factors for the infection, how to stop infection spread, the chances of recurrence, and treatment options for recurrent C. difficile. The 'C diff and You' app is an outstanding and user-friendly platform for patients to get accurate information on C. difficile infection and has resources that patients can use," says Sahil Khanna, M.B.B.S., M.S.

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About the C Diff Foundation

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation
#cdiffpatientfamilycaregiver #cdiff2021 #cdiffwalks2021

C Diff Foundation™ is a trademark of The C Diff Foundation, established 2012 in the U.S.

C Diff Foundation, the leading Global Patient and Healthcare Organization Educating and Advocating for C. difficile (Clostridioides difficile, C. diff., CDAD, CDI) today announced that the organization has developed a free mobile application designed specifically for patients and families who have been impacted by a Clostridioides difficile infection.

Related link: https://cdifffoundation.org/

C Diff Foundation Hosts Live-Online Symposium for Patients, Families and Caregivers

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, Jan. 15 from 1 to 4 p.m. EST. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection in addition to those who are recovering or who have experienced recurrences. The patients, family members and caregivers will all benefit from the information and up-to-date data presented.

Presenters are among some of the top C diff. thought leaders and include healthcare professionals, practitioners, educators and patients who are transforming the patient experience, and changing the way people experience C. diff. infections, worldwide.

Unlike other presentations on this topic, patients will share their C. diff. infection journeys, providing a real-world perspective on the patient experience. Other topics addressed will include creating a culture for patient-centered care, C. diff. innovations, diagnostics, research, environmental safety, clinical trials and studies, C diff. in pediatric patients and more.

All presentations will be designed for the lay person to easily understand and attendees will be able to ask questions directly to the keynote speakers via a live chat feature after each presentation.

"The live chat feature is one we're excited about and believe the attendees will embrace to have their questions answered by the keynote speakers," Nancy Caralla, C Diff Foundation founding president and executive director, says.

To register for this global event, visit: https://cdifffoundation.org/patientfamilyevent/

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20 percent, the C Diff Foundation believes that the annual incidence in the U.S. approaches 600,000.

About the C Diff Foundation

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission educating and advocating for C. diff. infection (CDI) prevention, treatments, clinical trials, environmental safety and support. Its mission continues to move forward and grow through research conducted by government, industry and academia strengthening the advocacy on behalf of patients, healthcare professionals and researchers, worldwide.

For more information: https://cdifffoundation.org/

About Seres Therapeutics

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

The Seres Therapeutics organization reported positive, topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI).

For more information: https://www.serestherapeutics.com/

MULTIMEDIA:

IMAGE link for media: https://www.Send2Press.com/300dpi/21-0113s2p-cdiff-symposium-300dpi.jpg

Caption: Register for the Patient and Family C Diff Foundation Symposium

MEDIA CONTACT:
Kathy Bischoff
of C Diff Foundation
+1-727-205-3922
kathy@cdifffoundation.org

The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, Jan. 15 from 1 to 4 p.m. EST. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection in addition to those who are recovering or who have experienced recurrences. The patients, family members and caregivers will all benefit from the information and up-to-date data presented.

Related link: https://cdifffoundation.org/

The C Diff Foundation Assures Patients C. diff. Clinical Trials Continue to Move Forward Safely

TAMPA, Fla. /ScoopCloud/ -- While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to the recent focus on the pandemic, the C Diff Foundation wants them to know they are not out of options. Safe and active clinical trials continue.

Most Clinical trial sites have implemented protocols to disinfect, clean and maintain environmental safety for all visitors. Telehealth is also being utilized between healthcare professionals and patients who choose to participate in clinical trials.

C. diff. continues to be a leading cause of infectious disease deaths and in the U.S., nearly half a million Americans suffer from it, according to the CDC. It's important for patients to know that research is still happening to combat this infectious disease.

Even during these unprecedented times, clinical trials continue to press onward to resolve CDI's. The C Diff Foundation's mission in educating and advocating for Clostridioides difficile awareness, prevention, treatments, diagnostics, clinical trials, and environmental safety, forges ahead utilizing live, and pre-recorded media to reach health care professionals, patients, families, and caregivers worldwide.

For more information, call the C Diff Foundation at: 727-205-3922, or email: info@cdifffoundation.com.

C Diff Foundation: https://cdifffoundation.org/.

Clinical trial information: https://clinicaltrials.gov/ and https://cdiffclinicaltrials.com/

About ClinicalTrials.gov

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

About the C Diff Foundation

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission of providing education for C. difficile infection prevention, treatments, environmental safety and support through research being conducted by the government, industry, and academia and provide better advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

MEDIA CONTACT:
Kathy Bischoff
of C Diff Foundation
+1-727-205-3922
kathy@cdifffoundation.org

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0111s2p-cdiff-clinical-300dpi.jpg

While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to the recent focus on the pandemic, the C Diff Foundation wants them to know they are not out of options. Safe and active clinical trials continue.

Related link: https://cdifffoundation.org/

2020 International Clostridioides difficile (C. diff., C. difficile) Virtual Conference and Health EXPO Nov. 14

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation announced today that the 8th Annual International C. diff. Virtual-Online Conference and Health EXPO will be a 5-1/2 hour online program with over fourteen international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile, Gut Microbiome, Infection Prevention, and global healthcare-associated issues on November 14, 2020 with a live online program under the direction of IT professionals at WhiteHat Communications.

To learn more about this extraordinary conference, guest speakers, poster presentations, and the diverse topics being presented visit: https://cdiff2020.com/guest-speakers-1

All attendees will have the highest levels of online networking and learning opportunity at the Conference and Health EXPO and registration is complimentary this year. Save the date: November 4th and 5th, 2021 the 9th Annual conference will be hosted at the Boston Logan Hilton Hotel in Boston, Mass.

C Diff Foundation expresses their gratitude to Seres Therapeutics for being the conference Diamond Sponsor. Seres Therapeutics is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide. This activity has been supported by a medical educational Grant from Pfizer and the members of the C Diff Foundation are profoundly grateful.

Attendee Paul Feuerstadt, MD, FACG, AGAF stated "The level of detail and data presented has a wonderful balance for those with an interest in the scientific research and interested in the infection but also exceeds the expectations for those who are experts in the field wanting to share and exchange ideas with other thought leaders."

"I am excited to virtually meet and interact with everyone for the online extraordinaire C difficile foundation 2020 meeting. We will discuss all things C difficile and remember to tune in for my talk on the excitement of microbiome therapeutics for recurrent C difficile," stated Sahil Khanna, M.B.B.S., M.S.

The scientific data will be delivered through live virtual presentations and poster presentations at the 8th Annual International C. diff. Virtual Conference and Health Expo https://cdiff2020.com which coincides with the proclaimed; "November is Clostridioides difficile (C. diff., C. difficile) Awareness Month."

Scott Battles, VP of the C Diff Foundation stated, "We are profoundly grateful to the United States Governors for supporting our mission, along with our domestic and international partners."

November 18 - 24, 2020 Be Antibiotics Aware, a CDC educational effort, complements U.S. Antibiotic Awareness Week by providing partners with up-to-date information to help improve human antibiotic prescribing and use in the United States.

"None of us can do this alone, all of us can do this together."

About Clostridioides Difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile or C. diff., is one of the most common causes of healthcare-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide.

Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. EST (www.cdiffradio.com) sponsored by Clorox Healthcare.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Download "C diff and You" app from Apple and Google Stores.

Twitter @cdiffFoundation #Cdiff2020

Media Contact:
Kathy Bischoff
C Diff Foundation
kathy@cdifffoundation.org
Office: (727) 205-3922

IMAGE LINKS FOR MEDIA:

[1] https://www.Send2Press.com/300dpi/30-1111s2p-cdiff8th-splash-300dpi.jpg

[2] https://www.Send2Press.com/300dpi/20-1111s2p-Cdiff640-920Conf-300dpi.jpg

C Diff Foundation announced today that the 8th Annual International C. diff. Virtual-Online Conference and Health EXPO will be a 5-1/2 hour online program with over fourteen international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Related link: https://cdifffoundation.org/

Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2 at ACG 2020

VENTURA, Calif. /ScoopCloud/ -- The American College of Gastroenterology (ACG) named Progenabiome "Outstanding Poster Presenter" for its poster: "Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection," which will be presented virtually at the ACG Annual Scientific Meeting this week. From close to 2900 posters, only roughly 10% were selected as outstanding posters.

Progenabiome will also present a second poster: "Detection and Mutational Analysis of SARS-CoV-2 From Patient Fecal Samples by Whole Genome Sequencing." The ACG 2020 Meeting will be held virtually on October 23-28, 2020, and both poster abstracts and presentations will be available online in the ACG 2020 ePoster Hall.

Last year, Dr. Sabine Hazan, CEO of Progenabiome, shared groundbreaking data on C.Diff discovered through genetic sequencing at the 2019 ACG Meeting. She is looking forward to sharing newly found data on C.Diff and also COVID-19 at this year's event.

Dr. Hazan also recently published new findings from a phase 2 trial on Eosinophilic Gastritis and Duodenitis in the New England Journal of Medicine (NEJM.) As a leading clinical trials investigator who has overseen more than 150 clinical trials, Dr. Hazan is dedicated to research and producing validated, verified, and reproduced data.

Strategically placed as a genetic sequencing lab, site, contract research organization (CRO), and now sponsor, Progenabiome has 41 ongoing clinical trials related to immunity and disease, including five COVID-19 studies validating testing, prophylaxis, and at-home treatment protocols for the novel coronavirus.

For more information, visit:
https://progenabiome.com

https://clinicaltrials.gov

https://malibumicrobiomemeeting.com/

ACG ePoster Hall: https://eventscribe.com/2020/ACGPosters/

NEJM paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2012047

Media Contact:
Stephanie Davis
sdavis@progenabiome.com

*IMAGE Link for Media: https://www.Send2Press.com/300dpi/20-1026s2p-Progenabiome-data-300dpi.jpg

The American College of Gastroenterology (ACG) named Progenabiome "Outstanding Poster Presenter" for its poster: "Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection," which will be presented virtually at the ACG Annual Scientific Meeting this week.

Related link: https://progenabiome.com/

C Diff Foundation Hosts 4th Annual Global C. diff. Awareness 2K Virtual Walks

TEANECK, N.J. /ScoopCloud/ -- C Diff Foundation announced today that registration is open for the 4th Annual Global C. diff. Awareness 2K Virtual Walks. This year's annual events will take place online and will be recorded at the Morris A. Votee Park, Teaneck, NJ, Charlestown Township Park, Phoenixville, PA, Sims Park, New Port Richey, FL on Saturday, September 12, 2020 from 8 a.m. - 12 p.m. ET. There will also be a superhero virtual show for super kids. Dr. Martha Clokie, Ph.D. will be leading the walk which will be recorded in Leicester, UK on Friday, September 11, 2020.

Registration is $20 per walker and complimentary for children 10 years of age and under. Learn more: https://cdifffoundation.org/cdiffwalk2020/

All registered awareness walkers will receive a t-shirt, giveaways, and educational material. Proceeds from the events will benefit the C Diff Foundation's mission educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. During these unprecedented times, caused by the COVID-19 pandemic, the C Diff Foundation effectively adapts to overcome the many obstacles developing from this global virus.

C. diff. infections are one of the leading healthcare-associated infections facing local communities worldwide. According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C. diff., C. difficile), (formally known as Clostridium difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"Every day the C Diff Foundation members work to educate and advocate for C. difficile infection prevention, treatments, clinical trials, and environmental safety while providing support worldwide," says Nancy Caralla, Founding President, and Executive Director of the C Diff Foundation. "Our dedication to the cause is making a difference as we share a common goal with government agencies and health care organizations witnessing a decrease in newly diagnosed C.diff. infections and saving lives. Our dedicated volunteering members, around the globe, are focused on improving the lives of individuals and families who are impacted by C. diff. infections."

We sincerely thank Vedanta Biosciences, Inc. for being the Diamond Sponsor of the 4th Annual Global C. diff. Awareness 2K Virtual Walks. Vedanta Biosciences, Inc. is dedicated to finding treatments for patients with serious infections and immune diseases. Vedanta develops medicines made of consortia of bacterial strains which are selected to effect robust and durable changes in a patient's gut microbiota.

In contrast to fecal transplants or administration of fecal fractions, Vedanta's medicines are pure, uniform compositions of bacteria manufactured from clonal cell banks, bypassing the need to rely on direct sourcing of fecal donor material of inconsistent composition. Vedanta is currently enrolling patients with recurrent C. difficile infections (CDI) in its CONSORTIUM study to evaluate VE303, an investigational treatment for CDI.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) supports public health through educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. For more information, or to find out how you can be a host of a Global C.diff. Awareness 2K Walk, visit http://www.cdifffoundation.org.

Follow C Diff Foundation on Twitter: @cdiffFoundation #CdiffWalk2020

Media Contact:
Kathy Bischoff, Global Walk Committee
kathy@cdifffoundation.org

*IMAGE LINK FOR MEDIA: https://www.Send2Press.com/300dpi/20-0819s2p-Cdiff-WALK-300dpi.jpg

C Diff Foundation announced today that registration is open for the 4th Annual Global C. diff. Awareness 2K Virtual Walks. This year's annual events will take place online and will be recorded at the Morris A. Votee Park, Teaneck, NJ, Charlestown Township Park, Phoenixville, PA, Sims Park, New Port Richey, FL on Saturday, September 12, 2020 from 8 a.m. - 12 p.m. ET.

Related link: https://cdifffoundation.org/

November Is C. diff. Awareness Month

NEW PORT RICHEY, Fla. /ScoopCloud/ -- The C Diff Foundation reemphasizes that the month of November is "C. diff. awareness month" and is being recognized with its partners around the globe again in 2019.

Nancy Caralla, Founding President, Executive Director of the C Diff Foundation, and three-time C. diff. Survivor said, "The month of November was chosen for two reasons. On November 1, 2012 the C Diff Foundation came to fruition. Also, after suffering through the second newly diagnosed CDI with nine-recurrences over a year's time, the month of November was chosen because it was the first month that I received a negative CDI test result without further recurrences."

Caralla further explained that over the past seven years other organizations and survivors, with their families, have joined the C Diff Foundation in "Raising C. diff. Awareness," especially in the month of November originally coined by the C Diff Foundation worldwide.

At the 7th Annual International C. diff. Awareness Conference and Health EXPO held in St. Louis, Missouri on November 6-7, the conference program included Government Agency healthcare professionals and representatives who delivered presentations focused on, but not limited to, Clostridioides difficile. Global organization health care professionals in attendance also recognize November is C. diff. Awareness Month through their presentations, posters, and by introducing products and/or services preventing, treating, diagnosing a CDI and maintaining safer environments in the healthcare community.

C Diff Foundation expresses their gratitude to the numerous state Governors who have recognized C. diff. infections as a leading Healthcare-associated infection by raising awareness during the month of November in their respected states.

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C. diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

Learn more at: https://cdifffoundation.org/

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. EST (http://www.cdiffradio.com/), sponsored by Rebiotix, a Ferring Pharmaceuticals company.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Kathy Bischoff
C Diff Foundation
kathy@cdifffoundation.org
Office: (727) 205-3922

The C Diff Foundation reemphasizes that the month of November is "C. diff. awareness month" and is being recognized with its partners around the globe again in 2019.

Related link: https://cdifffoundation.org/

C Diff Foundation’s Junior Infection Fighters Program Takes Action against Harmful Germs One Community at a Time Worldwide

NEW PORT RICHEY, Fla. /ScoopCloud/ -- C Diff Foundation announced today that the inaugural C Diff Foundation Junior Infection Fighter Program was introduced to families and their children/teens in Chester County, Pennsylvania on October 12, 2019.

Dayle Skelly, Director of the Junior Infection Fighter Program and C. diff. Survivor said, "There shouldn't be an age limit for raising awareness of infection prevention. Children are our future and take forth the torch of knowledge to be shared with everyone in each community."

The volunteer program has been developed for children/teens with the participation and support of their parents/legal guardian and supervision of C Diff Foundation adult volunteers. C Diff Foundation's Junior Infection Fighters Program mission: "To educate and advocate for infection prevention with the children and teens and to inspire their social, academic, personal, and health care knowledge and partner with parents who share the same mission to prepare them to be members of ever changing global health care in societies worldwide."

C Diff Foundation's Junior Infection Fighter guidelines have been brought to fruition, under the direction of a leading infection preventionist, Maureen Spencer, RN, M.Ed., CIC.

Ms. Spencer who has been an Infection Preventionist for over 30 years and board certified in infection control (CIC). As one of the early pioneers in infection control, she was awarded the APIC National Carole DeMille Award in 1990 and was selected as one of the APIC Heroes of Infection Prevention in 2007 for her work in establishing a MRSA and Staph aureus Elimination Program at New England Baptist Hospital, an Orthopedic Center of Excellence in Boston. The ground breaking work was published in the Journal of Bone and Joint Surgery

All volunteer attendees enjoyed spending time learning more about practicing healthy habits combined with infection prevention information during the inaugural community event.

"We work together to carve new paths in the multi-faceted patient and family programs offered by C Diff Foundation. Together we build awareness and advocate for C. diff. infection prevention, treatments, clinical trials, antibiotic-resistance, and environmental safety worldwide. We are truly grateful to the dedicated members taking the C Diff Foundation's mission to greater levels changing lives, and saving lives across the globe," said Nancy C. Caralla, Founding President, C Diff Foundation.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. ET (www.cdiffradio.com), sponsored by Rebiotix, a Ferring Pharmaceuticals company.

Learn more at: http://cdifffoundation.org

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Twitter @cdiffFoundation @Cdiff2019

Media Contact:
Dayle Skelly
Director Junior Infection Fighters Program
C Diff Foundation
info@cdifffoundation.org
Office: (727) 205-3922

*IMAGE link for media: https://www.Send2Press.com/300dpi/19-1015s2p-CdiffJuniorInfectionFighters-300dpi.jpg

###
Costs associated with dissemination of this news announcement were donated to the C Diff Foundation by NEOTROPE®, a California-based marketing company.

C Diff Foundation announced today that the inaugural C Diff Foundation Junior Infection Fighter Program was introduced to families and their children/teens in Chester County, Pennsylvania on October 12, 2019.

Related link: https://cdifffoundation.org/

C Diff Foundation Raises Clostridioides difficile Awareness in St. Louis on Nov. 6-7 at 7th Annual International Conference and Health EXPO

ST. LOUIS, Mo. /ScoopCloud/ -- C Diff Foundation announced today that the 7th Annual International C. diff. Conference and Health EXPO is honored to welcome over 30 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues on November 6 - 7, 2019 at the DoubleTree by Hilton Westport Hotel, 1973 Craigshire Road, St. Louis, MO 63146; Telephone: +1 (314) 434-0100.

To learn more about this extraordinary conference, guest speakers, and the diverse topics being presented visit: https://cdifffoundation.org/2019-guest-speakers/

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO.

C Diff Foundation expresses their gratitude to Pfizer for being the conference Diamond Sponsor. Pfizer is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide. This activity has been supported by an independent patient advocacy Grant from Merck & Co., Inc., and the members of the C Diff Foundation are truly grateful.

Attendee Paul Feuerstadt MD, FACG, AGAF stated, "The annual C Diff Foundation conference and health expo is an essential conference for me to attend, given the comprehensive presentations about epidemiology, disease state, patient experience, infection control and innovations with treatment of C. difficile. The level of detail and data presented has a wonderful balance that is understandable for someone casually interested in the infection but also exceeds the expectations for those who are experts in the field wanting to share and exchange ideas with other thought leaders."

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C. diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesday's at 1 p.m. EST (www.cdiffradio.com) sponsored by Rebiotix, a Ferring Pharmaceuticals company.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Angelo Ortiz
C Diff Foundation
angelo.ortiz@cdifffoundation.org
Office: (727) 205-3922

*IMAGE link for media: https://www.Send2Press.com/300dpi/19-1015s2p-cdiff-nov-expo-300dpi.jpg

C Diff Foundation announced today that the 7th Annual International C. diff. Conference and Health EXPO is honored to welcome over 30 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies. November 6 - 7, 2019 at the DoubleTree by Hilton Westport Hotel.

Related link: https://cdifffoundation.org/

C.diff. International Conference and Health EXPO Will Deliver Up-to-date Clostridioides difficile Data + More Nov. 6-7 In St. Louis

ST. LOUIS, Mo. /ScoopCloud/ -- The C Diff Foundation is honored to welcome 30+ international leading topic experts from hospitals, pharma, biotech, academia, and Government agencies to deliver and discuss critical information on global healthcare-associated issues.

To learn more about this extraordinary conference, agenda and guest speakers: https://cdifffoundation.org/2019-guest-speakers/

Clinical professionals will gather for two days to present up-to-date data to expand on the existing knowledge and raise awareness of the urgency focused on, but not limited to, Clostridioides difficile (formally known as Clostridium difficile) infection (CDI) Prevention, Treatments, Research, Diagnostics, Clinical trials, and Environmental Safety.

There will also be presentations exclusively concentrated on Infection prevention, Fecal microbiota restoration and transplants for adults, a Panel of C. diff. infection Survivors; a patient's perspective, Microbiome research, Scientific posters and poster presentations, Antibiotic stewardship, Antimicrobial resistance, and a Healthcare EXPO component.

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO. The conference program builds in time for face-to-face interaction between attending executives, corporate representatives and industry experts exhibiting.

C Diff Foundation expresses their gratitude to Pfizer for being the conference Diamond Sponsor. Pfizer is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide.

Attendee Linda Davis, RN, Patient Triage Specialist, said about the 2018 conference, "It's an excellent opportunity to have the ability to network with fellow-healthcare professionals from around the world. Each conference I have attended presents the opportunity to acquire knowledge with like-minded professionals striving to make a difference in the health care community. Attendees obtain the most innovative cutting-edge research and developments fighting today's complex world of healthcare-associated infections."

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C.diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. ET (www.cdiffradio.com), sponsored by Rebiotix, a Ferring Pharmaceuticals company, providing leading up-to-date information on topics that are aligned and connect with their organization's mission and more.

Learn more: https://cdifffoundation.org/

Follow C Diff Foundation on LinkedIn, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Angelo Ortiz
C Diff Foundation
angelo.ortiz@cdifffoundation.org
Office: (727) 205-3922

The C Diff Foundation is honored to welcome 30+ international leading topic experts from hospitals, pharma, biotech, academia, and Government agencies to deliver and discuss critical information on global healthcare-associated issues.

Related link: https://cdifffoundation.org/

World Renowned C Diff Foundation Announces First Ever Appointment of Paul Feuerstadt, M.D. as Director of Medical Education

NEW PORT RICHEY, Fla. /ScoopCloud/ -- C Diff Foundation, a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization, has appointed nationally renowned Gastroenterologist, Dr. Paul Feuerstadt as its first Director of Medical Education.

Dr. Feuerstadt said, "It is my honor to accept this position. I have been involved with the C Diff Foundation over the last 4.5 years and I look forward to assisting in the continued growth of the organization and ensuring that forward progress, awareness and education increases under my tenure. I look forward to working with the board and volunteers to increase awareness and funding across the country and around the world to highlight this disease through in person events, social media, and in the press."

Dr. Feuerstadt has spent his career refining his practice and expertise in C. difficile. He is dedicated to educating the public through his work with this organization.

Additionally, he plans to offer free patient and provider education through the launch of his new educational website, https://www.everythingcdifficile.com/. The goal of the site is to provide education through short videos with relevant clinical information for educational purposes. The site provides concise 3-5 minute lectures covering core topics, recent publications and major conferences about C. difficile infection to educate both patients and providers.

Nancy C. Caralla, Founding President, C Diff Foundation, commented: "Dr. Feuerstadt is a pre-eminent doctor in this space. His dedication and donation of his time and energy to this worthy cause has helped so many patients to date. We look forward to his enhanced leadership and knowledge as the organization grows and strengthens through our advocacy in the C.diff. community. Dr. Feuerstadt's new role as Director of Medical Education will provide an additional avenue of support to patients, families, and caregivers through his educational media available on EverythingCdifficile.com. We are grateful for Dr. Feuerstadt's time and dedication as we continue fighting this debilitating disease worldwide."

About C Diff Foundation:

The C Diff Foundation's mission is dedicated to reaching out to communities from villages to cities, to medical practitioners, medical students, C. diff. survivors, caregivers, and the patients combating a C. difficile infection (CDI) while providing the general public important information on prevention, treatments available, clinical trials in progress, and EPA registered products available for environmental safety.

The C Diff Foundation continues moving forward setting up outreach centers and building positive networks with the C Diff Foundation Volunteer Health Advocates aiding in "Raising C.diff. Awareness" worldwide.

Learn more: https://cdifffoundation.org/

About Dr. Paul Feuerstadt:

His areas of interest Clostridioides difficile infection and ischemic diseases of the gut and in these areas he has presented his research extensively, authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt's is teaching, frequently giving lectures locally, regionally and nationally. He holds a clinical appointment as an Assistant Clinical Professor of Medicine at the Yale University School of Medicine and is a full time attending physician at the Gastroenterology Center of Connecticut seeing patients with a broad spectrum of clinical gastroenterological diseases.

Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan for medical school and completed his residency in internal medicine at New York Presbyterian Hospital/Weill Cornell. His clinical fellowship training was completed at Montefiore Medical Center in the Bronx, New York.

About C.difficile:

It is the most common Healthcare-associated infection affecting an estimated 450,000 people annually in the United States alone with ~28,000 deaths from complications of this infection. This infection accounts for ~16% of all healthcare associated infections.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released February 25, 2015 by the Centers for Disease Control and Prevention CDC).

**Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections (CDI), making C. difficile a very important cause of infectious disease death in the United States alone. More than 80 percent of the deaths associated with C. difficile occurred among Americans aged 65 years or older. C. difficile causes an inflammation of the colon and deadly diarrhea.

C Diff Foundation, a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization, has appointed nationally renowned Gastroenterologist, Dr. Paul Feuerstadt as its first Director of Medical Education.

Related link: https://cdifffoundation.org/

C Diff Foundation Hosts 3rd Annual Global C.diff. Awareness 2K Walks

TEANECK, N.J. /ScoopCloud/ -- C Diff Foundation announced today that registration is now open for the 3rd Annual Global C.diff. Awareness 2K Walks. The events, which will take place at the Morris A. Votee Park, Teaneck, N.J., Charlestown Township Park, Phoenixville, Pa., and Sims Park, New Port Richey, Fla., will be hosted by the C Diff Foundation on Saturday, May 18, 2019 from 8 a.m. - 12 p.m.

Dr. Martha Cloakie, PhD will be leading the walk in Leicester, U.K. on Friday, May 17, 2019.

All registered awareness walkers will receive t-shirts, giveaways, and educational material while introducing the communities to the resources available. C.diff. infections are one of the leading healthcare-associated infections facing local communities.

Registration is $20.00 per walker and children 10 years of age and under walk free. https://cdifffoundation.org/3rdannualwalk/

Proceeds from the events will benefit the C Diff Foundation's mission educating and advocating for C.difficile infection prevention, treatments, clinical trials, and environmental safety worldwide.

According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C.difficile), (formally known as Clostridium difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"Every day the C Diff Foundation members work to educate and advocate for C. difficile infection prevention, treatments, clinical trials, and environmental safety while providing support worldwide. Our dedication to the cause is making a difference as we share a common goal with government agencies and health care organizations witnessing a decrease in newly diagnosed C.diff. infections and saving lives. Our dedicated volunteering members, around the globe, are focused on improving the lives of individuals and families who are impacted by C.diff. infections," says Nancy Caralla, Founding President, and Executive Director of the C Diff Foundation.

We sincerely thank Vedanta Biosciences, Inc. for being the Diamond Sponsor of the 3rd Annual Global C.diff. Awareness 2K Walks. Vedanta Biosciences, Inc. is dedicated to finding treatments for patients with serious infections and immune diseases. Vedanta develops medicines made of consortia of bacterial strains which are selected to effect robust and durable changes in a patient's gut microbiota.

In contrast to fecal transplants or administration of fecal fractions, Vedanta's medicines are pure, uniform compositions of bacteria manufactured from clonal cell banks, bypassing the need to rely on direct sourcing of fecal donor material of inconsistent composition. Vedanta is currently enrolling patients with recurrent C. difficile infections (CDI) in its CONSORTIUM study to evaluate VE303, an investigational treatment for CDI.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) supports public health through educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. For more information, or to find out how you can be a host of a Global C.diff. Awareness 2K Walk visit http://www.cdifffoundation.org.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#CdiffWalk2019

The C Diff Foundation announced today that registration is now open for the 3rd Annual Global C.diff. Awareness 2K Walks. The events, which will take place at the Morris A. Votee Park, Teaneck, N.J., Charlestown Township Park, Phoenixville, Pa., and Sims Park, New Port Richey, Fla., will be hosted by the C Diff Foundation on Saturday, May 18, 2019 from 8 a.m. - 12 p.m.

Related link: https://cdifffoundation.org/